Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 20/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23976767 | 0.91 | CETP (0.78) | CETP | |
| SCHEMBL23977183 | 0.90 | CETP (0.77) | CETP | |
| SCHEMBL23977232 | 0.89 | CETP (0.76) | CETP | |
| SCHEMBL23976782 | 0.89 | CETP (0.82) | CETP | |
| Dalcetrapib SCHEMBL29350009 | 0.85 | CETP (1.00) | CETP | |
| Dalcetrapib SCHEMBL528622 | 0.85 | CETP (1.00) | CETP | |
| SCHEMBL528587 | 0.85 | CETP (1.00) | CETP | |
| SCHEMBL528436 | 0.85 | CETP (0.76) | CETP | |
| SCHEMBL23976791 | 0.85 | CETP (0.76) | CETP | |
| SCHEMBL2679960 | 0.85 | CETP (0.86) | CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | DALCOR PHARMA UK LTD., LEATHERHEAD, ZUG BRANCH (CH) | 2021-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210338626-A1 | METHODS FOR TREATING OR PREVENTING A VIRAL INFECTION OR INHIBITING VIRAL REPLICATION | ACE, ACE2, REN | CETP 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.